Karyopharm Therapeutics Inc. (KPTI) Stock Rating Reaffirmed by Jefferies Group LLC
KPTI has been the subject of a number of other research reports. Cantor Fitzgerald set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the stock a buy rating in a research report on Thursday, October 12th. Royal Bank Of Canada initiated coverage on shares of Karyopharm Therapeutics in a research report on Thursday, September 14th. They set an outperform rating and a $14.00 price objective for the company. Robert W. Baird restated an outperform rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, July 4th. Canaccord Genuity set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the stock a buy rating in a research report on Tuesday, August 8th. Finally, ValuEngine downgraded shares of Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Thursday, August 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $15.38.
Karyopharm Therapeutics (NASDAQ KPTI) opened at 11.38 on Friday. The stock’s market cap is $536.43 million. Karyopharm Therapeutics has a 12-month low of $6.27 and a 12-month high of $14.63. The firm has a 50 day moving average of $10.86 and a 200-day moving average of $9.89.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. The business’s revenue was down 95.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.84) earnings per share. On average, analysts expect that Karyopharm Therapeutics will post ($2.62) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/10/16/karyopharm-therapeutics-inc-kpti-stock-rating-reaffirmed-by-jefferies-group-llc.html.
In other news, Director Mansoor Raza Mirza sold 2,882 shares of the stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $11.00, for a total value of $31,702.00. Following the completion of the transaction, the director now owns 2,882 shares in the company, valued at approximately $31,702. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 10,695 shares of company stock valued at $118,950 in the last quarter. Insiders own 14.71% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Voya Investment Management LLC increased its holdings in shares of Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after purchasing an additional 4,444 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $136,000. American International Group Inc. increased its holdings in shares of Karyopharm Therapeutics by 20.9% in the 1st quarter. American International Group Inc. now owns 16,422 shares of the company’s stock valued at $211,000 after purchasing an additional 2,836 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $202,000. Finally, State of Wisconsin Investment Board purchased a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $235,000. Institutional investors and hedge funds own 58.97% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.